Supreme Court denies W.L. Gore in stent graft patent spat with C.R. Bard

Tue, 01/15/2013 - 5:00am
Mass Device

The U.S. Supreme Court refuses to hear an appeal from W.L. Gore & Assoc. in a patent war with C.R. Bard over stent graft technology.

C.R. Bard logo
W.L. Gore & Associates logo
The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.

Last October Gore asked the Supremes to consider its appeal of a $186 million patent loss to Bard.

Today the high court denied that bid, whereupon Bard promptly filed a motion to compel payment in the U.S. District Court for Arizona, according to a regulatory filing.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.